Clinical Trials Logo

Congenital Heart Disease clinical trials

View clinical trials related to Congenital Heart Disease.

Filter by:

NCT ID: NCT01045252 Active, not recruiting - Sepsis Clinical Trials

Study of Hemodynamics of Neonates by Echocardiography and USCOM

HNEU
Start date: October 2008
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the hemodynamic values of neonates that are healthy and those with various congenital heart diseases and sepsis by using echocardiography and USCOM.

NCT ID: NCT01006629 Completed - Clinical trials for Congenital Heart Disease

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

Start date: November 2009
Phase: Phase 2/Phase 3
Study type: Interventional

100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe respiratory syncytial virus (RSV) infection in order to study the safety and efficacy of the drug in Russian subjects.

NCT ID: NCT00994994 Completed - Clinical trials for Congenital Heart Disease

Tranexamic Acid in Pediatric Cardiac Surgery

TXA
Start date: January 2006
Phase: N/A
Study type: Interventional

Tranexamic acid(TXA) is an antifibrinolytic agent to reduce blood loss in cardiac surgery. Previous seven RCTs comparing effects of TXA in pediatric cardiac surgery showed conflict results. The reason why they showed mixed results would be the imbalance of patients population with regard to presence of cyanosis. TXA would reduce blood loss in pediatric cardiac surgery with well balanced patients population.

NCT ID: NCT00989911 Completed - Clinical trials for Congenital Heart Disease

Endothelin Blockade in Patients With Single Ventricle Physiology

Start date: May 2010
Phase: N/A
Study type: Interventional

Recent studies have shown beneficial effects of sildenafil in patients with single ventricle congenital heart disease. The purpose of this study is to determine whether Bosentan, a drug with similar effects, will have similar benefit in this patient population.

NCT ID: NCT00934843 Completed - Clinical trials for Congenital Heart Disease

Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass

Start date: March 2007
Phase: N/A
Study type: Interventional

Randomized controlled trial of the use of glucocorticoids to improve the clinical course of neonates post-cardiopulmonary bypass (CPB).

NCT ID: NCT00930800 Completed - Clinical trials for Congenital Heart Disease

Exercise Training in Children With Congenital Heart Defect

Start date: December 2007
Phase: N/A
Study type: Interventional

The purpose of this study was to investigate the effects of exercise training on exercise capacity, physical activity (PA), health-related quality of life (HRQoL), and the psychosocial factors affecting PA in sedentary congenital heart defect (CHD) children and healthy sedentary children. The degree of improvement after exercise training were compared between CHD children and healthy sedentary children.

NCT ID: NCT00919945 Terminated - Clinical trials for Congenital Heart Disease

Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn

Start date: January 2009
Phase: Phase 2
Study type: Interventional

The objective of this study is to determine the impact of early post-operative feeding on splanchnic blood flow, cardiac output and end organ perfusion, and the patients overall clinical outcomes.

NCT ID: NCT00911833 Completed - Hypertension Clinical Trials

The Roles of Trust and Respect in Patient Reactions to Race-based and Personalized Medicine Vignettes: An Experimental Study

Start date: May 19, 2009
Phase: N/A
Study type: Observational

Background: - Genetic research has implications for drug development and marketing. Race-based medicine may be able to provide specific treatment for populations with increased disease-specific morbidity and mortality. However, contemporary genetic research refutes the idea that races are genetically distinct populations, even as drugs designed for use in specific races are being promoted. - Studies have shown high levels of public suspicion for race-based and personalized genetic medicine. Concerns related to not only the potential performance of race-based drugs, but also the motives of those offering these drugs. Many participants have suggested conspiracy theories in which race-based medicine was disguising an attempt to provide inferior medications or deliberately harm certain populations. Concerns about personalized medicine often have to do with privacy and other personal concerns. - Public suspicions of race-based medicine, and to a lesser extent, personalized genetic medicine, make it important to examine and understand the theoretical and empirical literature on trust and health care. Objective: - To describe the perspective of participants evaluating the medicine offer. Eligibility: - Males and females ages 18 and older who are visiting the John Hopkins clinics (primarily the adult care clinics). - Participants must be able to take a literacy screen and respond to a short survey. Design: - Participants will be asked to take a researcher-administrated literacy screen, read one of three randomly assigned vignettes, and fill out a survey. The first page of the survey will provide information about the study. - Participants will respond to initial questions about demographics, experiences with discrimination, and trust in the medical profession and institutions. - Each participant will receive a random vignette in which he/she will imagine him/herself being diagnosed with a common, chronic condition and offered a conventional drug, a race-based drug, or a genetically personalized drug. - After being presented with the vignette, participants will be asked to respond to a survey that asks about their levels of trust in the vignette doctor, perceived respect given to the patient by the vignette physician, emotional response to the vignette, their belief in the effectiveness and safety of the drug prescribed in the vignette, information sufficiency, and their hypothetical behavioral intention to take the drug. - Participants will be debriefed after completing the survey, and will be offered a small amount of compensation for participating.

NCT ID: NCT00868101 Completed - Clinical trials for Congenital Heart Disease

The Effect of Remote Ischemic Preconditioning Applied in Children the Day Before Open Heart Surgery

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The study research is to analyse brief episodes of limb ischemia applied to children the day before open heart surgery as protection from myocardial injury induced by extracorporeal circulation.

NCT ID: NCT00850720 Terminated - Clinical trials for Congenital Heart Disease

Study of Possible Brain Hormone Problems After Open Heart Surgery in Infants

Start date: March 2009
Phase: N/A
Study type: Observational

The goal of this study is to evaluate specific hormone levels in children undergoing heart surgery in order to identify patterns associated with any unstable vital signs. The data collected will provide preliminary answers to the question "Are hormone values a determining factor for drug administration and dosing levels?" and help establish the benefits of routine steroid and hormone administration. Sixty subjects will be enrolled. Blood samples will be drawn before the surgery,and again nine hours after surgery for analysis. Other patient data such as medications, vital signs, routine lab values and treatments will also be analyzed. As our current standard of care includes routine doses of steroids, we believe this study will increase our general knowledge and improve the care of these critically ill children. The study will also provide the foundation needed for grant support from the American Heart Association, allowing for future larger scale studies.